tbuckley/cabot-search huggingface dataset:
Melanopsin Effects on Pupil Responses
Authors: Owen B. White, Fiona Costello
Journal: JAMA Neurology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
A Phase IIIb Multicentre Open-Label Study of Nilotinib in Adult Patients with Newly Diagnosed BCR-ABL Positive Chronic Myeloid Leukemia (CML) in Chronic Phase (CP): A European Clinical Initiative with EUTOS Collaboration for Standardisation of Molecular Remission
Authors: Francis J. Giles, Gianantonio Rosti, Gert Ossenkoppele, Michel Tulliez, Jesper Stentoft, Aristoteles Giagounidis, Francesco Nobile, Philipp D. le Coutre, Norbert Gattermann, Laimonas Griskevicius, Nicholas C.P. Cross, Sarah Hill, Peter Schuld, Angela Pellegrino, Domenico Magazzù, Andreas Hochhaus
Journal: Blood (2011)
Donor B Cells in Transplants Augment Clonal Expansion and Persistence of Pathogenic Donor CD4+ T Cells in Autoimmune-Like Chronic Graft-Versus-Host Disease,
Authors: James Sundblom Young, Tao Wu, Yuhong Chen, Dongchang Zhao, Heather F Johnston, Xiaofan Li, Stephen J. Forman, Defu Zeng
Journal: Blood (2011)
Feasibility, accuracy and prognosis of sentinel lymph node biopsy before neoadjuvant therapy in breast cancer. A prospective study
Authors: Amparo Garcia-Tejedor, Catalina Falo, Cecilia Quetglas, Teresa Soler, Belen Marqueta, Raul Ortega, Miguel Gil-Gil, Sonia Pernas, Eulalia Fernandez-Montolí, Maria J Pla, Anna Guma, Maite Bajen, Ana Benitez, Arantxa Eraso, Miriam Campos, Anna Petit, Jordi Ponce
Journal: International Journal of Surgery (2017)
A Phase I Trial of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), in Combination with Rituximab (R) and Bendamustine in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma (NHL)
Authors: Kristie A. Blum, Beth Christian, Joseph M. Flynn, Samantha M. Jaglowski, Jeffrey Alan Jones, Kami Maddocks, John C. Byrd
Journal: Blood (2012)
A Multicenter Phase II Trial of Unrelated Donor Reduced Intensity Bone Marrow Transplantation for Children with Severe Sickle Cell Disease (SCURT): Results of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0601) Study
Authors: Shalini Shenoy, Mary Eapen, Juan Wu, Mark C. Walters, John E. Levine, Brent Logan, Iris D. Gersten, Naynesh R. Kamani
Journal: Blood (2015)
CBM-17INCREASING EXPRESSION OF GLUTAMINASE C (GAC) mRNA IN MALIGNANT GLIOMAS
Authors: Kazuhiro Tanaka, Takashi Sasayama, Yasuhiro Irino, Hiroaki Nagashima, Naoko Satoh, Paul Mischel, Eiji Kohmura
Journal: Neuro-Oncology (2015)

BACKGROUND: Metabolic reprogramming is the biological hallmarks of cancer cells. Glutamine metabolism, as well as aerobic glycolysis known as the Warburg effect, participate in energy formation, redox homeostasis and micromolecular synthesis to enhance tumor growth and keep malignancy, but the clinical implications are not well understood. AIMS: Through an integrated analysis of clinical glioma imaging and samples, we examined the importance of glutamine metabolism. METHODS: To identify the expression of in vivo metabolites, metabolic profiling of tumor targets from preoperative imaging was performed with MR spectroscopy (MRS) and analyzed by LC-model software in 37 glioma patients. The expression of enzymes to regulate glutamine metabolism was examined in 30 glioma samples obtained by surgical resection. RESULTS: MRS data showed that glutamine, glutamate and glutathione levels were significantly higher in glioblastomas (GBMs, WHO grade IV) than in low grade gliomas (WHO grade II) (Tukey-Kramer honest significance test, P< 0.05). Gene expression analysis demonstrated that the levels of solute-linked carrier family A1 member 5 (SLC1A5, glutamine transporter) and glutaminase C (GAC), a splice variant of glutaminase (GLS) were frequently elevated in GBMs (P< 0.05). Interestingly the expression of c-Myc was significantly correlated with GAC levels in GBMs (correlation coefficient r = 0.5855, p < 0.01). CONCLUSIONS: Glutamine metabolism plays an important role in malignant glioma. GAC could be useful diagnostic markers and therapeutic targets in the treatment of patients.
Mutation Analysis of TET2 Reveals the Clonal Nature of Refractory Anemia with Ring Sideroblasts
Authors: Luca Malcovati, Angela Brisci, Anna Gallì, Francesca Bruno, Erica Travaglino, Andrea Pellagatti, Matteo G Della Porta, Maurizio Ferrari, Jacqueline Boultwood, Laura Cremonesi, Eva Hellström-Lindberg, Mario Cazzola
Journal: Blood (2010)
hTERT, the Catalytic Component of Telomerase, Is Down-Regulated in the Hematopoietic Stem Cells of Patients with Chronic Myeloid Leukemia.
Authors: Lisa J. Campbell, Helen Eagleton, Tim J. Littlewood, Andy Peniket, Rajko Kusec, Shira Gal, Carrie Fidler, James S. Wainscoat, Jacqueline Boutlwood
Journal: Blood (2004)
Fotemustine (MUFORAN) in Combination with Once Weekly Bortezomib and Dexamethasone (B-MuD): Good Clinical Activity and Favourable Toxicity Profile for Treatment of Relapsed Multiple Myeloma Patients.
Authors: Silvia Mangiacavalli, Alessandra Pompa, Lara Pochintesta, Cristiana Pascutto, Federica Cocito, Mario Cazzola, Alessandro Corso
Journal: Blood (2012)
Atrial Fibrillation, Type 2 Diabetes, and Non–Vitamin K Antagonist Oral Anticoagulants
Authors: Anna Plitt, Darren K. McGuire, Robert P. Giugliano
Journal: JAMA Cardiology (2017)

<h3>Importance</h3> Atrial fibrillation (AF) is the most common cardiac arrhythmia and is associated with a 5-fold increase in the risk for stroke. Type 2 diabetes is an independent risk factor for both stroke and atrial fibrillation, and in the setting of AF, type 2 diabetes is independently associated with a 2% to 3.5% increase in absolute stroke rate per year. The overlap in the pathophysiologies of AF and type 2 diabetes are not well understood, and current practice guidelines provide few recommendations regarding patients with both conditions. <h3>Observations</h3> In this article, we review the epidemiology and pathophysiology of the nexus of AF and type 2 diabetes. Furthermore, we analyze the subgroup of patients with type 2 diabetes enrolled in phase 3 clinical trials of non–vitamin K antagonist oral anticoagulants in prevention of arterial thromboembolism in AF, highlighting the greater absolute benefit of non–vitamin K oral anticoagulants in patients with type 2 diabetes. Finally, we offer recommendations on risk stratification and therapy for patients with concomitant AF and type 2 diabetes. <h3>Conclusions and Relevance</h3> We highlight the increased thromboembolic risk with coexisting AF and type 2 diabetes. We recommend that further studies be done to evaluate the potential benefits of anticoagulation for all patients who have both and the potential for non–vitamin K oral anticoagulants to have greater benefits than risks over vitamin K antagonists.
Seeing how we smell
Authors: Helene Benveniste, Yuri Lazebnik, Nora D. Volkow
Journal: Journal of Clinical Investigation (2017)

PET allows noninvasive imaging of a variety of events in the body, including the activity of neuronal circuits in the brain that are involved in cognition and behaviors, by using radiotracers that detect relevant biological reactions. A major impediment to expanding PET applications to study the brain has been the lack of radiotracers that can identify and measure specific types of neurons or glial cells. In this issue of the JCI, Van de Bittner and colleagues describe a promising step toward solving this problem by identifying and describing a radiotracer, [11C]GV1-57, that appears to specifically label olfactory sensory neurons (OSNs), which are essential for olfaction (Figure 1). This tracer, if its specificity is confirmed, has the potential to become a prototype for future radiotracers that can identify other neuronal cell types and would allow visualization and in-depth characterization of these neurons and their genesis.
Accelerated telomere shortening in glycosylphosphatidylinositol (GPI)–negative compared with GPI-positive granulocytes from patients with paroxysmal nocturnal hemoglobinuria (PNH) detected by proaerolysin flow-FISH
Authors: Fabian Beier, Stefan Balabanov, Tom Buckley, Klaus Dietz, Ulrike Hartmann, Markus Rojewski, Lothar Kanz, Hubert Schrezenmeier, Tim H. Brümmendorf
Journal: Blood (2005)
Nicotine reverses hypofrontality in animal models of addiction and schizophrenia
Authors: Fani Koukouli, Marie Rooy, Dimitrios Tziotis, Kurt A Sailor, Heidi C O'Neill, Josien Levenga, Mirko Witte, Michael Nilges, Jean-Pierre Changeux, Charles A Hoeffer, Jerry A Stitzel, Boris S Gutkin, David A DiGregorio, Uwe Maskos
Journal: Nature Medicine (2017)
Concomitant Presentation of Acute Myeloid Leukemia (AML) and Lung Cancer
Authors: Ramya Varadarajan, LaurieAnn Ford, Sheila NJ Sait, Annemarie W. Block, Maurice Barcos, Paul K. Wallace, Nithya Ramnath, Eunice S Wang, Meir Wetzler
Journal: Blood (2008)
Prevalence of HIV infection among people with disabilities: a population-based observational study in Yaoundé, Cameroon (HandiVIH)
Authors: Pierre De Beaudrap, Gervais Beninguisse, Estelle Pasquier, Alice Tchoumkeu, Adonis Touko, Frida Essomba, Aude Brus, Toyin Janet Aderemi, Jill Hanass-Hancock, Arne Henning Eide, Muriel Mac-Seing, Daniel Mont
Journal: The Lancet HIV (2017)
Linkage of Safety Information to Regulatory Action
Authors: Jon Resar, Myron L. Weisfeldt
Journal: New England Journal of Medicine (2017)

The evolution of medical devices during the past 50 years has had a major positive effect on human health — and we can be certain that the devices that are available now will change substantially over time. We can also be certain that complications and failures associated with such devices that are not identified at the time of approval for human use will appear over time. This is the challenge of regulatory science with respect to medical devices.Although the delivery of pharmaceutical and biologic agents may change, the parent chemical compound or biologic entity does not change over time. . . .
Survival update from a multicenter, randomized, phase III trial of vitespen versus observation as adjuvant therapy for renal cell carcinoma in patients at high risk of recurrence
Authors: C. G. Wood, P. Srivastava, L. Lacombe, A. I. Gorelov, S. Gorelov, P. Mulders, H. Zielinski, F. Teofilovici, L. Isakov, B. Escudier
Journal: Journal of Clinical Oncology (2009)

3009 Background: Vitespen (formerly HSPPC-96) is a novel, autologous, heat shock protein (gp96)-peptide complex vaccine. The survival registry is investigating long-term efficacy of vitespen in renal cell carcinoma (RCC) patients at high risk for recurrence postnephrectomy. Methods: Eligible patients were enrolled and active in Antigenics’ C-100–12 phase III protocol, with a last survival status of alive at study end. Patients randomized in C-100–12 (1:1, vitespen vs. observation) had AJCC stage I (T1b), II (≥5 cm; Fuhrman grade 3/4), stage III, or stage IV (M0) RCC, ≥25% clear cells, ECOG performance score 0/1 and ≥7 g viable tumor tissue for vaccine production. The registry's primary objective is to assess OS. Registry patients are contacted every 6 (no recurrence) or 3 (upon recurrence) m, for a total of 3 y from final C-100–12 data cutoff. Results: Upon C-100–12 termination, 513 of 728 patients were eligible for follow-up. Currently, 306/513 (60%) patients are in the registry database; 207 patients are being contacted. The cohort of 306 patients is well balanced by C-100–12 randomization arm: (59.8% vitespen, 59.5% observation). Formal statistical analyses are in process. Descriptively, updated OS data show a favorable trend in the vitespen arm vs. observation in all analysis sets, especially among patients with earlier-stage disease (stage I/II high grade; n = 118) or at intermediate risk for recurrence (stage I/II high grade, III T1, T2, T3a, low grade; n = 184 ), with 13/125 (10.4%) vs. 21/115 (18.3%), and 18/184 (9.8%) vs. 33/178 (18.5%) deaths reported in the vitespen and observation arms, respectively. Conclusions: The registry provides an opportunity to confirm whether the emerging survival advantage demonstrated at the data cutoff for the C-100–12 trial improves with prolonged follow-up. Formal statistical analyses are ongoing; data available to date show continuing signals of clinical benefit associated with vitespen treatment in patients with better prognostic factors. [Table: see text]
Atopic dermatitis and early childhood caries: Results of the GUSTO study
Authors: Tosha Ashish Kalhan, Evelyn Xiu Ling Loo, Ashish Chetan Kalhan, Michael S. Kramer, Bindu Karunakaran, Carolina Un Lam, Hugo Van Bever, Lynette Pei-chi Shek, Anne Goh, Yap Seng Chong, Bee Wah Lee, Peter Gluckman, Kenneth Kwek, Seang Mei Saw, Keith Godfrey, Chin-Ying Hsu
Journal: Journal of Allergy and Clinical Immunology (2017)
Siglec-7 Tetramers Characterize B Cell Subpopulations and Identify Immunomodulatory Ligands on Malignant Cells
Authors: Philippa Mang, Friederike Gieseke, Susanne Viebahn, Inga Gondesen, Anne Kruchen, Annika Erbacher, Matthias Pfeiffer, Rupert Handgretinger, Ingo Müller
Journal: Blood (2010)
Female Donor Allografts Have a Higher CD3 Content Than Male Donor Allografts: Potential Impact On Transplantation Outcomes in Male Recipients
Authors: Moshe Yeshurun, Ron Ram, Ofer Shpilberg, Corina Herscovici, Liat Vidal, Tsila Zuckerman, Nuhad Haddad, Jacob M Rowe, Ronit Yerushalmi, Arnon Nagler, Avichai Shimoni
Journal: Blood (2012)
Phase I Trial of Bortezomib (PS-341; NSC 681239) and Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory Indolent B-Cell Neoplasms - Update of the “Bolus” Infusion Schedule of Alvocidib.
Authors: Beata Holkova, Edward B. Perkins, Prithviraj Bose, Daniel M Sullivan, Rachid Baz, Mary Beth Tombes, Ellen Shrader, Viswanathan Ramakrishnan, Wen Wan, Heidi Sankala, Maciej Kmieciak, John D. Roberts, Steven Grant
Journal: Blood (2012)
RETRACTED: Long Noncoding RNA LINC00673 Is Activated by SP1 and Exerts Oncogenic Properties by Interacting with LSD1 and EZH2 in Gastric Cancer
Authors: Mingde Huang, Jiakai Hou, Yunfei Wang, Min Xie, Chenchen Wei, Fengqi Nie, Zhaoxia Wang, Ming Sun
Journal: Molecular Therapy (2017)

Long noncoding RNAs (lncRNAs) have emerged as important regulators in a variety of human diseases, including cancers. However, the biological function of these molecules and the mechanisms responsible for their alteration in gastric cancer (GC) are not fully understood. In this study, we found that lncRNA LINC00673 is significantly upregulated in gastric cancer. Knockdown of LINC00673 inhibited cell proliferation and invasion and induced cell apoptosis, whereas LINC00673 overexpression had the opposite effect. Online transcription factor binding site prediction analysis showed that there are SP1 binding sites in the LINC00673 promoter region. Next, luciferase reporter and chromatin immunoprecipitation (ChIP) assays provided evidence that SP1 could bind directly to the LINC00673 promoter region and activate its transcription. Moreover, mechanistic investigation showed that CADM4, KLF2, and LATS2 might be the underlying targets of LINC00673 in GC cells, and RNA immunoprecipitation, RNA pull-down, and ChIP assays showed that LINC00673 can interact with EZH2 and LSD1, thereby repressing KLF2 and LATS2 expression. Taken together, these findings show that SP1-activated LINC00673 exerts an oncogenic function that promotes GC development and progression, at least in part, by functioning as a scaffold for LSD1 and EZH2 and repressing KLF2 and LATS2 expression. Long noncoding RNAs (lncRNAs) have emerged as important regulators in a variety of human diseases, including cancers. However, the biological function of these molecules and the mechanisms responsible for their alteration in gastric cancer (GC) are not fully understood. In this study, we found that lncRNA LINC00673 is significantly upregulated in gastric cancer. Knockdown of LINC00673 inhibited cell proliferation and invasion and induced cell apoptosis, whereas LINC00673 overexpression had the opposite effect. Online transcription factor binding site prediction analysis showed that there are SP1 binding sites in the LINC00673 promoter region. Next, luciferase reporter and chromatin immunoprecipitation (ChIP) assays provided evidence that SP1 could bind directly to the LINC00673 promoter region and activate its transcription. Moreover, mechanistic investigation showed that CADM4, KLF2, and LATS2 might be the underlying targets of LINC00673 in GC cells, and RNA immunoprecipitation, RNA pull-down, and ChIP assays showed that LINC00673 can interact with EZH2 and LSD1, thereby repressing KLF2 and LATS2 expression. Taken together, these findings show that SP1-activated LINC00673 exerts an oncogenic function that promotes GC development and progression, at least in part, by functioning as a scaffold for LSD1 and EZH2 and repressing KLF2 and LATS2 expression.
Haploidentical Unmanipulated G-CSF-Primed Peripheral Blood Stem Cell Transplantation for Patients with High-Risk Hematologic Malignancies
Authors: Dai-Hong Liu, Li Yu, Wenrong Huang, Liping Dou, Honghua Li, Chunji Gao, Jian Bo, Fei Li, Lili Wang
Journal: Blood (2015)
Historical Perspective on the Rise and Fall and Rise of Antibiotics and Human Weight Gain
Authors: Scott H. Podolsky
Journal: Annals of Internal Medicine (2017)

In recent medical and popular literature, audiences have been asked to consider whether antibiotics have contributed to the rising obesity epidemic. Prominent magazines have stated that weight may be adversely affected by antibiotics that destroy existing microbiomes and replace them with less helpful ones. However, there is a long history of efforts to investigate the relationship between antibiotics and human weight gain. In the early 1950s, amid initial findings that low doses of antibiotics served as growth promoters in animal livestock, investigators explored the role of antibiotics as magic bullets for human malnutrition. Nevertheless, early enthusiasm was tempered by controlled studies showing that antibiotics did not serve as useful, nonspecific growth promoters for humans. In subsequent decades, against the backdrop of rising concern over antibiotic resistance, investigators studying the role of antibiotics in acute malnutrition have had to navigate a more complicated public health calculus. In a related historical stream, scientists since the 1910s have explored the role of the intestinal microflora in human health. By the 2000s, as increasing resources and more sophisticated tools were devoted to understanding the microbiome (a term coined in 2001), attention would turn to the role of antibiotics and the intestinal microflora in the rising obesity epidemic. Despite scientific and commercial enthusiasm, easy answers (whether about antibiotics or probiotics) have again given way to an appreciation for the complexity of human growth. History encourages caution about our hopes for simplistic answers for presumed "fat drugs" and slimming probiotics alike.
Incidence and Characterization of Taste Disturbances After Allogeneic or Autologous Hematopoietic Stem Cell Transplantation Using Myeloablative or Reduced-Intensity-Conditioning.
Authors: Birgit Federmann, Jens Weidmann, Gunnar Blumenstock, Silke Schwarz, Lothar Kanz, Frank Mayer, Wolfgang Andreas Bethge
Journal: Blood (2009)
Reduced-Intensity Unrelated Cord Blood Transplantation (RICBT) for Myelofibrosis (MF).
Authors: Shinsuke Takagi, Shigesaburo Miyakoshi, Yasunori Oota, Daisuke Kato, Tomomi Kawano, Eiji Kusumi, Tomoko Matsumura, Koichiro Yuji, Naoyuki Uchida, Kazuhiro Masuoka, Atsushi Wake, Akiko Yoneyama, Shuichi Taniguchi
Journal: Blood (2005)
Effect of sex-hormone levels, sex, body mass index and other host factors on human craniofacial bone regeneration with bioactive tricalcium phosphate grafts
Authors: Christine Knabe, Aynur Mele, Peter Herbert Kann, Barbara Peleska, Doaa Adel-Khattab, Harald Renz, Alexander Reuss, Marc Bohner, Michael Stiller
Journal: Biomaterials (2017)
Meal Timing and Frequency: Implications for Cardiovascular Disease Prevention: A Scientific Statement From the American Heart Association
Authors: Marie-Pierre St-Onge, Jamy Ard, Monica L. Baskin, Stephanie E. Chiuve, Heather M. Johnson, Penny Kris-Etherton, Krista Varady
Journal: Circulation (2017)

Eating patterns are increasingly varied. Typical breakfast, lunch, and dinner meals are difficult to distinguish because skipping meals and snacking have become more prevalent. Such eating styles can have various effects on cardiometabolic health markers, namely obesity, lipid profile, insulin resistance, and blood pressure. In this statement, we review the cardiometabolic health effects of specific eating patterns: skipping breakfast, intermittent fasting, meal frequency (number of daily eating occasions), and timing of eating occasions. Furthermore, we propose definitions for meals, snacks, and eating occasions for use in research. Finally, data suggest that irregular eating patterns appear less favorable for achieving a healthy cardiometabolic profile. Intentional eating with mindful attention to the timing and frequency of eating occasions could lead to healthier lifestyle and cardiometabolic risk factor management.
Expansion of Large Granular Lymphocytes Following Allogeneic Stem Cell Transplantation: Its Association with Graft-Versus-Host Disease and Graft-Versus-Leukemia Effect.
Authors: Dong Hwan (Dennis) Kim, Ghuzayel Al-Dawsari, Chul Won Jung, Chang Hong, Suzanne Kamel-Reid, Janice Wright, Ahmed Galal, Vikas Gupta, John Kuruvilla, Jeffrey H. Lipton, Hans A. Messner
Journal: Blood (2009)
Hyper Immunoglobulin E Syndrome (HIES): Report of a New Case Treated with Omalizumab and Dexametasone
Authors: Luis Fernando Cortázar-Benítez, R.M. Rojas Sotelo, Pablo Vargas-Viveros, Rafael Hurtado-Monroy, Catalina Romo Aguirre, Jorge Valenzuela Tamariz, Alejandra Zárate, Sergio Masse
Journal: Blood (2011)